Skip to main content

Table 4 Analysis for combinational biomarkers

From: Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Variables

Combinations

Mutation+

Mutation-

Mutation+

Mutation-

Mutation+

Mutation-

Mutation+

Mutation-

P

1068+

1068+

1068-

1068-

1068+

1068+

1068-

1068-

-

1173+

1173+

1173+

1173+

1173-

1173-

1173-

1173-

-

Total

35(22.4)

42(26.9)

5(3.2)

8(5.1)

30(19.2)

19(12.2)

2(1.3)

15(9.6)

-

ORR

CR + PR

16(45.7)

7(16.7)

1(20.0)

1(12.5)

20(66.7)

5(26.3)

0

0

<0.001

DCR

CR + PR + SD

28(80.0)

26(61.9)

3(60.0)

1(12.5)

29(96.7)

17(89.5)

1(50.0)

8(53.3)

<0.001

PD

7(20.0)

16(38.1)

2(40.0)

7(87.5)

1(3.3)

2(10.5)

1(50.0)

7(46.7)

PFS

Median (months)

6.3

3.1

4.6

1

12.8

6.6

0.4

1.4

<0.001

  1. Abbreviations: pTyr, phophorylated tyrosine; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival, 1068 pTyr1068, 1173 pTyr1173.